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Abstract
Chronic wounds present many clinical challenges in relation to the successful treatment
and closure of the damaged tissue. Most current treatment methods focused on one or two aspects
to drive wound closure, while most chronic wounds are multifactorial environments with many of
those dependencies relying on the termination of one another to effectively gain tissue
construction, closure, and full skin thickness and composition. Natural wound healing processes
allude to potential biologics that can impede the chronic breakdown of tissue, while restoring
deposition of new tissue, and effectively leading to a healed wound. Proteases secreted by the
body’s immune system lay waste to even the healthy tissues in wounds, which can be seen in
those that turn chronic, as a progressive and persistent break down of tissue, proteins, and cells in
the wound site. The disruption of this exacerbated tissue breakdown is both essential to quell the
destruction of healthy tissues as well as other proteins such as growth factors that are needed to
signal for the development and deposition of new tissue. The latter points to the importance of the
balance between tissue break down and deposition, commonly referred to as remodeling, as a
focusing point for the healing of chronic wounds. The two generalized secreted molecules that
balance tissue breakdown and deposition are proteases and growth factors respectively. However,
the efficacy of growth factors that exist in a wound site are highly dependent upon the
concentration of secreted proteases. Therefore, in chronic wounds the proteases which are
continuously secreted, without intrinsic inhibition, will chew up the growth factors responsible for
signaling deposition, which causes tissue destruction to be the overpowering and vicious result.
The protein-based combination therapy created here works to rebalance tissue breakdown and
vii

deposition to tend toward minimal deconstruction with overpowering construction. It works by
inhibiting proteases, flooding the site with many growth factors, while also sustaining the presence
of the treatment over longer periods to avoid site disturbance and leakage of the biologic
combination into neighboring tissues. This protein combination is a powder-based freeze dried
therapeutic, that can be used in powder form or reconstituted into many mediums and materials
for desired application and results. It is a multifunctional treatment, with the main controlling
factor for application being wound size as a governing guideline for dosage, as it can be applied
in many different forms such as raw powder, liquid, gel, and in materials for an application tailored
to the characteristics of the treatment site.
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Chapter 1: The Clinical and Economic Burden of
Chronic and Hard-to-Heal Wounds
Wound care and the impact of a growing population presenting delayed wound healing has
been an enormous conversation for decades regarding its economic and clinical impacts. Despite
widespread concern, it has been observed that the treatment of chronic wounds has not advanced
beyond rudimentary techniques to help spike wound closure and minimize the progression of other
diseases that accompany wounds, such as infection. Infection remains a heavy collateral burden
when treating hard-to-heal wounds (HtHWs). The longer a wound stays open, the greater the
opportunity for bacteria to establish around the nutrients of a gaping wound. Once established,
infection perpetuates the issue of chronicity through the breakdown of healthy tissue into bacterial
nutrients. Both the clinical and economic success of a chronic wound is a time dependent issue,
where the time it takes to close a wound determines the primary outcome of how hard to heal the
wound may be through the addition of further tissue insult and is directly related to the clinical
commitment and economic requirements to utilize therapies long term to eventually obtain wound
closure.
Chronic and HtHWs affect a broad range of patient demographics and age groups either
affected by associated diseases that lead to HtHWs or due to physical and environmental impacts
from lifestyle activities. It is seen that over a decade ago, in 2009, 6.5 million patients in the United
States presented chronic wounds, racking up an annual treatment bill of $25 billion dollars1. While
in 2018, targeting an “at risk” population, an analysis of only Medicare beneficiaries reported 8.2
million patients being treated for wounds with an estimated range of total costs to treat being
1

roughly $28 - $97 billion2. With current statistics and economic impacts being a complex analysis,
the observational truth that underfunding wound care research and poor regulation in regenerative
medicine industries, shed light on the fact that wounds continue to progress in impact, but nothing
has been successfully developed and translated to shunt the impact of HtHWs, in a downward
projection, on both the patient and the economy. In fact, as recent as 2021, the Department of
Defense (DOD) has published white papers regarding combat wounding being the leading cause
of death on the battlefield, stating that affordable therapeutics have not yet been made to withstand
the hardships of healing a wound in the field3. In further analysis the DOD believe that wound
healing has been underfunded, underdiscussed, and products have been inhibited from translation
into the market in a timely and cost-effective manner3. The latter places an important aspect of
healing hard-to-heal wounds and that is the impact local environmental factors have on wound
healing. An expansion of this idea is that even weather-related environmental factors may elevate
the risk to develop a HtHW. For example, tropical environments, which can be wet and warm, act
as perpetuators of chronic wounds as the climate is more favorable for the spread and establishment
of bacteria within a wound. An understanding of who, where, and when in the wound healing
phase seems to be the foundational factors of successfully healing a delayed wound. However, the
more important factor is quite simply the inner environment of the wound, since human tissues all
heal the same way, if wound closure is achieved before time dependent factors like who the patient
is and what the environment they live in and how it exacerbates issues in the wound healing
process. This understanding is essential when developing wound care products because the process
of treating the wound can then be strikingly universal. With the right product, and clinician focus
on eliminating the complexities of the problem, can be accomplished by simply focusing on
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interrupting the awry system shunting the bodies response to a wound and ultimately moving it
toward the remodeling phase.
A chronic wound has been commonly defined as a wound that fails to heal within a threemonth period4. But, from a physiological perspective, a chronic or HtHW is simply a wound where
the healing process halts within a tissue deconstruction phase, while never establishing new
healthy tissue and structure4-6. The latter happens well before the 3-month classification making
intervention an immediate need rather than a need at the three-month mark. On the surface of the
body, a proper wound healing process, from damage to closure, consists of 4 simplified phases.
The normal wound healing is shown in Figure 1. Upon tissue trauma the first phase of healing is
hemostasis and blood clot formation followed by inflammation and tissue breakdown queued by
stimulated and migrated immune cells in the wound site. Once the damaged tissue is degraded the
wound quickly enters the third phase where cellular migration and proliferation of healthy tissue
occur. The fourth and last phase of a healthy wound healing cycle consists of tissue remodeling
where the wound is closed, and tissue architecture is completely restored. HtHWs remain in the
step where tissue breakdown and tissue clearance, seen by the governing immune system, as most
important. This is due to the overabundance of proteases secreted by local cells, essentially causing
a vicious cycle where tissue deconstruction overpowers tissue reconstruction leading to a festering
open wound.
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Figure 1. Steps of the Wound Healing Processes in an Acute Wound

Current treatments for delayed wounds have been around for decades and remain basic.
Treating a persistent wound normally takes the initial form of a clinician’s understanding of why
a patient presents a chronic wound7, 8. This is a systemic evaluation of overall health, pinpointing
connected diseases like diabetes and heart disease, where the symptomatic characteristics of these
diseases are linked to why a wound may not be healing. Additionally, immunological disorders,
or a body’s self-infliction of damage, can hurl the normal wound healing process into a cycle where
tissue is constantly broken up in the wound site, while never establishing the steps necessary for
4

tissue reconstruction9. The very nature of a systemic outlook on a HtHW can be overwhelming
for clinicians and though a systemic disease may be the forefront contributor to the formation of a
wound with delayed healing, it must never be treated as the main cause. It may be completely
necessary to manage systemic diseases that support HtHW formation, or impede closure, but a
chronic wound may never heal just by a clinicians focus on diminishing a contributing disease but
rather keeping a costly wound open while doing so. The root cause is simply a local imbalance, in
the wound site, causing tissue breakdown to supersede tissue reconstruction6, 7, 10-13. The focus for
healing HtHWs should be placed on restoring this imbalance and closing the wound fast to
minimize widespread burden on the patient and the economy. Then managing systemic problems
become important as they may contribute to a healed wound’s relapse back to chronicity.
Traditional treatment methods still hold their place as valuable procedures and therapies to
aid in wound closure. Debridement, which is a removal of dead tissues from a wound is a
necessary step, not for the immediate healing of the wound, but rather for optimal delivery of
effective therapeutics. The treatment of chronic or HtHWs may, by necessity, include antibiotics
to rid the wound site of bacterial infection. But again, this is a secondary method of therapy where
the primary focus, restoring balance in tissue breakdown and tissue construction, will close a
wound fast and further prevent time for secondary contributors to delayed wound healing. The
body’s immune system and cellular response are responsible for the breakdown of damaged tissue
through the secretion of proteinases that target the tissues structural components and delay
healing12. This is a complex process that involves different cell types and their associated protease
secretions, but it is well known what secretions are responsible for the breakdown of different
tissue types like neutrophil elastase (NE) and matrix metalloproteinase-2 (MMP2)7, 14, 15. An added
aspect of tissue degradation in chronic and HtHWs is an established bacterial infection leading to
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further proteolytic degradation10, 12, 16. Bacteria secrete their own metalloproteinases to aid in a
competitive establishment and acquire the nutrients necessary to expand and take over a wound
site5, 7. However, this displays commonality across two different contributing factors to HtHWs.
That is in one case it is our body oversecreting tissue degrading enzymes, and in the case of bacteria
they also secrete tissue degrading proteases to survive, grow, and compete. The latter draws
importance to the fact that it does not matter what the case is, the result is tissue breakdown.
Inhibiting tissue breakdown is absolutely key in pursuing closure of a delayed wound and can be
done easily by targeting secreted proteases that are commonly found at high levels in chronic
wounds. Tissue construction is heavily reliant on the secretion of protein growth factors which
contain an important role in cell migration, proliferation, and cellular matrix secretion17. However,
the same proteases that break down wounded tissue, also wreak havoc on any proteins present in
the site18, which includes the very important growth factors needed to remodel. The prior will keep
the wound halted in a deconstruction phase. Without the necessary growth factors present, cellular
migration and proliferation will happen on a very low level if not at all. The proteases present in
chronic wounds destroy healthy tissue and viable signaling proteins, ultimately halting the normal
wound healing process in a vicious loop that only focuses on deconstructing the wound site.
The problem described here can be answered with the replacement of biological switches
that aid in progressing the wound further in the healing cycle. This can be done utilizing proteinbased protease inhibitors12, 13, 18. Once protease inhibition is established, the risk of proteolytic
degradation of tissue and useful growth factors is minimized, then the HtHW can move forward
into the remodeling phase, where signaling for migration and proliferation can occur minimizing
destruction of the signaling molecules. Here, protease inhibitors are the “off-switch” to the vicious
cycle of tissue degradation in a in a wound with delayed healing, while the “on-switch” is the
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addition of growth factors and cytokines that can aid in remodeling. However, it is critical that
both “switches” exist together as they are mutually beneficial to progressing the wound toward
closure. The protease inhibitors protect the tissue and additionally the growth factors, since the
phase of wound healing cannot move forward without proper signaling from the growth factors.
Once both effects are established, together, the HtHW will progress towards closure.
A wound healing strategy to target hard-to-heal wounds was formulated to interrupt this
system of balance of tissue destruction and deposition, while keeping in mind the economic
impacts and inherent burdens the current treatment of chronic and HtHWs incur. A protein-based
therapeutic was designed as a three-component system that includes a multifunctional protease
inhibitor, a conditioned media for inducing cellular proliferation, and an additional extracellular
matrix binding protein to target and extend delivery of the protease inhibitors around essential
tissue structures that are susceptible to proteolytic degradation. While keeping in mind factors
related storage and ease of use of a product, it was created to be a freeze-dried, powder-based
product, with an extended shelf-life, and ease of application of a powdered product that for
example is less affected by factors such as gravity on a flowing liquid. Additionally, the threecomponent system is made and processed in a way where there exist only 3 components to
synthesize and then mix. Each of the three components inherently include multiple functions.
Therefore, instead of making a three-component system with three functionalities, this is a threecomponent system with many more than three functionalities without adding additional systems
or steps to acquire them. In other words, this product can be made with 3 bioreactors and then
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mixed, rather than 10+ bioreactors to gain each functionality through inherently separate systems,
which drives down cost and time to produce.
Through clinical evidence the proteases to be targeted by the 1 component, multifunctional
inhibitor were human neutrophil elastase (HNE) and matrix metaloproteinase-2 (MMP2)11, 12, 14,
18, 19

. The utilization of an elastin-like peptide (ELP) core centered between two corresponding

protease inhibitors, PMP-D2 and APP-IP, respectively, is essential to create an easily editable and
expandable platform, which can be synthesized and purified rapidly while maintaining unique
bioactivities of each region. The ELP serves multiple functions, the two most important being selfassembly for purification via inverse phase transitioning (ITC) and application, while an additional
important function of the ELP is to serve as a molecular spacer between unique biologically active
regions that must contain availability and spatial requirements for proteases to bind, and for the
inhibitors to act specifically and simultaneously on target proteases. However, ELP fusion proteins
created in this manner are incredibly hard to purify, if not impossible to purify any considerable
amount of peptide due to repulsive forces of similarly charged bioactive ends. Therefore, a process
established by the authors has been applied and denoted as pI-Based Phase Separation (pI-BPS),
which utilizes pH changes to neutralize repelling charges that make self-assembly and therefore
purification impossible at a neutral pH. This challenge and solution give way to another potential
loss of functionality at the level of therapeutic application. ELP fusions have traditionally been
utilized to create a sustained release of the therapeutic, since they will assemble and aggregate at
body temperature20. However, if a constructed protein cannot be purified effectively at a neutral
pH utilizing ITC, then it most definitely won’t self-assemble in the application site due to these
charge hinderances, if not transitioned at a pH close to the protein’s pI. Given this new problem
and the pursuit to create a product that can be site specific and minimize treatment repetitions, an
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additional ELP fusion protein was created to aid in the sustained release and low diffusivity of the
product.
A hybrid tethering protein was constructed and added to the dry wound healing product to
act as a molecular tether that spans from the inhibitors’ ELP regions to binding regions on
extracellular matrix (ECM) proteins. Consisting of a placental growth factor (PlGF-2), known for
affinity to ECM proteins21, and a free ELP end, the binding protein can act as a tether with the
protease inhibitor fusion proteins, when the dual protease inhibitor cannot effectively selfassemble. This acts as a fail-safe for maintaining protease inhibitor in the wound bed, and around
the ECM that is drastically affected by high concentrations of proteolytic enzymes, thus
maintaining the components that are already present, and healthy, while cellular migration and
proliferation is elevated by the protein cocktail.
Furthermore, a proliferation inducing component, possibly containing a soup of wellknown wound healing peptides and proteins22 secreted by umbilical cord derived mesenchymal
stem cells ultimately exists as a blend of freeze-dried peptides that can be applied to a wound to
spike proliferation and remodeling. Utilizing synthesis and processing protocols established by the
author, allows for the production of a highly potent and consistent mesenchymal stem cell
conditioned media. Challenges with culturing mesenchymal stem cells for this purpose include
slow doubling rates, low-passage senescence, and variability in resulting conditioned medias.
However, through established screening methods for proliferation induction, a culturing process
was established, and useful biproducts of UM-MSCs can be used to effectively to cause
proliferation and aid in the closure of a wound if protected from the powerful effects of proteases.
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Chapter 2: Fusion Protein Construction and Expression
2.1 Materials
Plasmids containing the genes for L10-Flag, PMP-D2, APP-IP, and PlGF2 were obtained
from GenScript® ,optimized for corresponding cutting sites for the restriction enzymes PflMI and
BglI to exclude cuts within the genes of interest, and includes a gene for resistance to carbenicillin
for effective colony isolation. Restriction enzymes (PfLM1 & BglI) and ligase for the recombinant
process were obtained by New England Biolabs® Inc. Table 1 displays the amino acid sequences
for the correlated genes of interest ordered in pUC57 or pUC19.

Table 1. The amino acid sequences for the construction of the ELP fusion proteins
L10-Flag
((VPGVG)2(VPGLG)(VPGVG)2)10
PMP-D2

EEKCTPGQVKQQDCNTCTCTPTGVWGCTLMGCQPA

APP-IP

ISYGNDALMP

PlGF2

RRPKGRGKRRREKQRPTDCHL

2.2 The Construction of Recombinant ELP Fusion Proteins
The ELP fusion proteins used in this therapeutic mixture were constructed using cloning
and recombinant technology in microorganisms. Described by the author prior13, pUC57 and
pUC19 plasmids containing PMP-D2, APP-IP and L10-Flag were cloned in Top10 and purified to
a desirable working concentration for recombinant processes. The plasmid containing L10-Flag
was linearized using the restriction enzyme, PflMI. PMP-D2’s nucleic acid sequence was cut out
10

of the pUC57 plasmid utilizing both restriction enzymes, PflMI and BglI, and purified to obtain a
PMP-D2 fragment. The PMP-D2 fragment and the linearized pUC19 L10-Flag plasmid were then
spliced together utilizing recursive directional ligation to obtain the circular plasmid, PMPD2L10Flag pUC19. After cloning an isolated bacterial colony containing the new plasmid, PMPD2L10Flag pUC19, the nucleic acid sequence for PMPD2-L10Flag was fragmented out of the pUC19
plasmid. APP-IP in a pUC57 plasmid was linearized and a recursive directional ligation was
performed to yield PMPD2-L10Flag-APPIP in a pUC57 plasmid. The gene of interest was then
double cut using PflMI and BglI, then spliced into a linearized pET25b plasmid for expression in
BLR(DE3) e coli.
The nucleic acid sequence for L10Flag-PlGF2 was made similarly to that of the inhibitor.
It was designed so that the ELP region is free for tethering to other proteins. A pUC57 plasmid
containing the gene encoding for the PlGF2 protein was linearized. Simultaneously, L10-Flag was
fragmented out of a pUC19 plasmid. A recursive directional ligation was performed between L10Flag fragment and the linearized PlGF2 pUC57. The resulting circular pUC57 plasmid contained
the gene encoding for L10Flag-PlGF2. L10Flag-PlGF2 nucleic acid sequence was fragmented
from the pUC57 plasmid, ligated into a circular pET25b plasmid, and transformed into BLR(DE3)
e coli.
All constructed ELP fusion proteins are verified via Sanger Sequencing. The results of
Sanger Sequencing for PMPD2-L10Flag-APPIP and L10Flag-PlGF2 are seen in Figure 2 & 3.
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Figure 2. Sanger Sequencing Results for PMPD2-L10Flag-APPIP. PMPD2 Fused to the NTerminus of L10Flag. And APPIP Fused to the C-Terminus of L10Flag
12

Figure 3. Sanger Sequencing Results for L10Flag-PLGF. PLGF Fused to the N-terminus of
L10Flag.

2.3 Expression and Purification of ELP Fusion Proteins
After transformation into BLR(DE3) e coli, a single colony for each desired fusion protein
was used to inoculate a separate 75 mL of terrific broth (TB) supplemented with carbenicillin.
After 12 hours incubating at 37°C with agitation, the 75 mL for each protein to be expressed and
purified was transferred into a liter of TB supplemented with carbenicillin. A 24-hour incubation
at 37°C with agitation was performed on each culture. After a 24-hour incubation, the cultures
were centrifuged to separate the bacteria containing the expressed proteins from the TB. The

13

bacterial pellets were each resuspended in 160 mL of cold 1xPBS and lysed utilizing three
sonication and mixing steps. Once lysing is complete the protein and bacterial lysate samples were
centrifuged at 4°C, twice, to separate the bacterial debris from the solubilized fusion proteins in
the supernatants. Inverse Transition Cycling (ITC) is utilized to separate the ELP fusion proteins
from debris. ITC begins by the addition of NaCl to each sample to a final 4 molar concentration.
It is important to note, a new procedure was implemented into a standard ITC protocol where
before a hot centrifugation, the pH of each sample is adjusted to match the pI of each protein, while
before a cold spin the pH is adjusted back to a neutral pH or to a pH extreme depending on protein
net protein charge. This process is coined pI-Based Phase Separation (pI-BPS), and necessary to
obtain useable protein yields when purifying dual fusions, like PMPD2-L10Flag-APPIP. Each
sample was placed in a 45°C hot bath for 15 to 30 minutes (depending on how quickly each sample
transitions). After hot centrifugation, the transitioned protein pellets were separated from the
supernatants, and resuspended in 100 mL of cold 1xPBS. Once evenly resuspended and the pH
adjustment is made, the samples undergo a cold centrifugation at 4°C. After the cold
centrifugation, the supernatants containing the proteins are collected and separated from the pellets
containing debris. The hot centrifugation and cold centrifugation alternation and collection with
the appropriate pH adjustments are performed repeatedly until the final protein product is cleared
of debris. Once resolved, the final protein pellets are resuspended in 50 mL of deionized H2O and
dialysis is performed for 24 hours.

Once dialysis is complete, the protein solutions were then

frozen at -80°C and then lyophilized until freeze dried completely.
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Chapter 3: Verification of pI-Based Phase Separation for the
Purification and Application of ELP Fusion Proteins
Protein charge is based on the charge of each residue that comprises the overall amino acid
sequence for a particular protein. Isoelectric point (pI) is a solution pH where a protein exhibits a
net zero charge. PI-BPS was verified useful through experimental observation of protein yields
resulting from inverse transition cycling, quantification of transitioning at a neutral pH and at a
protein’s pI evaluated by absorbance over temperature changes, and dynamic light scattering.
Table 2 displays ELP fusion proteins, their sequences, and isoelectric point tested in the
absorbance-based transitioning experiments, while not all were evaluated by dynamic light
scattering.

Table 2. Complete fusion protein sequences and their isoelectric points for each protein studied
using pI-BPS
Protein
Sequence
Isoelectric
Point (pI)
L10Flag
((VPGVG)2(VPGLG)(VPGVG)2)10-DYKDDDDK
3.74
PMPD2L10Flag-APPIP
L10Flag-PlGF2

EEKCTPGQVKQQDCNTCTCTPTGVWGCTLMGCQPA
–((VPGVG)2(VPGLG)(VPGVG)2)10-DYKDDDDKISYGNDALMP
((VPGVG)2(VPGLG)(VPGVG)2)10-DYKDDDDKRRPKGRGKRRREKQRPTDCHL

4.10

9.35

15

3.1 Hypothesis Behind the Charge Dependency of ELP Transitioning
Unsuccessful purification of ELP-fusion proteins such as, PMPD2-L10Flag-APPIP, lead
to a hypothesis that ELPs centered between two bioactive regions with similar charge polarities
are hindered during temperature dependent aggregation and will not self-assemble to a degree
necessary for bulk phase separation. Figure 4 displays the ELP self-assembling behavior at a
neutral pH, for three different cases of fusions. Figure 4A displays the case where there is a unfused
ELP. An ELP without fusions is completely unhindered by charges because the ELP sequence is
largely non-polar allowing for easy phase separation at a neutral pH. This can be seen in Figure
4A where the ELPs readily aggregate at a temperature (T) above that of the ELPs’ transitioning
temperature (Tt). Figure 4B presents a case of ELP fusion that contributes hinderance to the overall
behavior of aggregation. This case is a single charged fusion at one end of the ELP. Though ELP
transitioning can still occur, the degree of transitioning is controlled by the charge density of the
fused domain on the end of the ELP. In Figure 4B the aggregate formed is highly dependent on
how close two identically charged ends, from two individual molecules, can get before repulsive
charges limit ELP interactions at the core of the aggregate. Additionally, Figure 4C shows another
case where there is a charged domain fused to each end of the ELP creating a molecule with a nonpolar ELP core and two ends of the molecule containing similar repulsive charges. In this case, at
a neutral pH, little to no aggregation will be accomplished when solution T≥Tt because individual
molecules and their ELPs will never get close enough to interact and self-assemble due to the
repulsive forces between the ends of each bioactive domain during intermolecular interaction.
The reversable elimination of charges on the ends of ELP-fusion proteins allow for the
self-assembly and phase transition necessary to utilize ELPs and their transitioning capabilities for
purification and application. PH variations of a protein solution to the protein’s isoelectric point
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can reversibly neutralize charges to allow for aggregation when deemed useful. For example, for
protein purification, inverse transition cycling of ELP-fusion proteins can be utilized when highly
charged bioactive ends exist through the employment of pH adjustments before hot centrifugations
by adjusting the solution pH to the protein’s isoelectric point (pI). This eliminates charges for as
long as the pH is at the proteins pI. In Figure 5, this hypothesis is observed, and suggests when a
protein solution pH is adjusted to that of the protein’s pI, ELP interactions are therefore enabled
(when T≥Tt) through the elimination of repulsive charges that exist during an intermolecular
interaction at a neutral pH in Figure 4C.
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A.

pH=7.4

B.

pH=7.4

C.

pH=7.4

Figure 4. ELP-Fusion Protein Transitioning Behavior for A) Unfused ELPs, B) Single ELP
Fusions, and C) Dual ELP Fusions.
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Figure 5. Transitioning Behavior of Dual ELP Fusions Utilizing pI-Based Phase Transitioning.

3.2 Quantifying ELP Fusion Protein Transitioning Utilizing Absorbance Measurements
Various ELP fusion proteins were reconstituted at a neutral pH and at a specific protein’s
isoelectric point, where the net charge of the entire protein molecule is zero. Utilizing the known
amino acid sequences for each ELP fusion protein and an online (isoelectric.org) isoelectric point
calculator to calculate the pH where each protein of interest has a zero net charge. The isoelectric
point calculator is based upon the use of Henderson-Hasselbach equation, and dissociation
constants of positive and negative residues to approximate a protein’s charge at a given pH.
PMPD2-L10Flag-APPIP and other various proteins were solubilized at its calculated pI and at 7.4
pH. Then in a 96-well plate, the samples were arranged in triplicate. Due to the experimental design
and nature of transitioning experiments, correlated blanks of each buffer pH were included. The
plate with samples were placed in a BioTek Synergy HT microplate reader, utilizing the software,
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Gen5, for a kinetic assay, varying temperature overtime while recording OD360. The temperature
start point was 30°C and the 96-well plate was preheated to the start temperature before the first
reading. The following temperature and read points were at 35, 40, and 45°C. Before each read,
there was a delay to account for machine warm up and time for sample transitioning at a particular
temperature. Table 2 displays each ELP fusion protein, and their approximate pI used in the
purification of these proteins, and in the described experiments.
3.3 Dynamic Light Scattering Experiments
Dynamic Light Scattering (DLS) was performed on samples of both L10Flag and PMPD2L10Flag-APPIP to better understand the phase separation behavior of these ELP fusion proteins
at the protein’s isoelectric points and in a neutral pH. A Malvern Zetasizer ZEN 1600, by Malvern
Panalytical Ltd., was used to perform all DLS experiments. The DLS protocol was designed to
measure size distribution of assembling ELP fusion proteins over a series of temperatures. The
protocol begins with a temperature set point of 10°C, then increasing the temperature in 5°C
increments with the last DLS measurement at 45°C. After the sample reaches each temperature set
point, size distribution and correlogram data was measured and recorded. This experiment is
performed on both L10Flag at a neutral pH and PMPD2-L10Flag-APPIP at a neutral pH and at its
pI. The resulting DLS data is analyzed in Excel to plot size distribution and associated correlogram
data.
3.4 Absorbance Results for pI-BPS of ELP Fusion Proteins
Absorbance measurements of transitioning for ELP fusion proteins confirmed the
importance of pI-BPS for the purification and application of these fusion proteins. L10-Flag is the
most basic ELP fusion protein that we work with and contains little hinderance to transition since
any charge on this protein is from the fusion of a Flag-tag end. Figure 6A represents a graph of
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L10 Flag and the degree of transitioning over a range of temperatures at 7.4 and 3.8 pH. Here, it
is seen that L10Flag transitions to nearly the same degree at its pI and above its Tt the sample
transitions like at a neutral pH. However, at or near L10Flag’s transition temperature it is clear that
the sample at its pI transitions nearly 5-fold better than at a neutral pH. Figure 6B displays
transitioning results of the dual protease inhibitor, PMPD2-L10Flag-APPIP. It is clear that pI-BPS
is needed for the ITC purification of this protein. Over the range of tested temperatures, the protein
sample at a neutral pH, did not have an elevated increase in absorbance due to transitioning. In
fact, the level of transitioning stayed very similar over the tested temperature ranges. At PMPD2L10Flag-APPIP’s pI, 4.1 pH, the transition steadily increased over the range of temperatures
reaching a 6-fold increase in absorbance than that of the sample in a neutral buffer.
Through a ITC purification process of PMPD2-L10Flag-APPIP, it was clear that pI-BPS
implemented in the ITC protocol was absolutely necessary to maximize protein yield just by
observation of end result. Purifying two batches of PMPD2-L10Flag-APPIP alongside one
another, with one batch kept at a neutral pH throughout, and the other following pH adjustments
for hot centrifugation spins at the proteins PI, further proved the necessity of pI-BPS. The yield in
protein for the PMPD2-L10Flag-APPIP, at its pI, was a 22.5-fold increase over the protein yield
of the sample that remained at a neutral pH throughout.
Samples of PMPD2-L10Flag-APPIP were further analyzed at the proteins pI and at 7.4 pH.
Samples were transitioned and viewed under a microscope to observe size differences in selfassembled particles. Figure 7 A and B show qualitatively the very large difference in particle size
when each solution is heated. This observational result further shows the effect of pI-BPS on ELPbased fusion proteins and their transition dependency on solution pH (or protein charge).
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3.4.1 Sources of Error and Variability
Standard deviation was calculated for the absorbance experiments and applied to each
respective bar of the graphs of absorbance over a rang of temperatures. Here in this experiment the
propagation of error is likely due to aspects related to temperature range in the microplate reader
as temperature is varied. Since the microplate reader heats up from the sides, the center of the plate
may be cooler than the edges. To overcome this source of variance the experiment was ran utilizing
the center of the 96-well plate, while excluding the wells at the edge of the plate. Also, a wait
period was utilized to ensure that the entire plate was evenly warmed to the set temperature before
a reading was taken.
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Figure 6. A Display of the Degree of Transitioning of L10Flag and PMPD2-L10Flag-APPIP a
Neutral pH and at the Protein’s Isoelectric Point. A) L10Flag at a neutral pH and its pI. B) PMPD2L10Flag-APPIP at a neutral pH and its pI

A.
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A.
B.

B.

Figure 7. Microscopy Imaging of Transitioned PMPD2-L10Flag-APPIP. A) At PMPD2L10Flag-APPIP’s pI B) PMPD2-L10Flag-APPIP at a neutral pH
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3.5 Dynamic Light Scattering Analysis of Particle Size Formation Utilizing PI-BPS
The DLS data further confirms what has been observed with microscopy, absorbance
experiments for transitioning, and purification results. Figure 8 A-C represents the size distribution
data collected on L10Flag from 10-40°C. Figure 8A shows particle size data of a un-transitioned
sample of L10Flag in a neutral buffer at 10°C, which displays a small particle size in low amount.
Figure 8B shows L10Flag’s particle size distribution at 30°C, where it can be observed that a small
shift to a larger particle size is taking place with transitioning beginning to occur. Transitioning is
apparent in Figure 8C displaying L10-Flag transitioning further at 40°C, which is indicated by a
further peak shift, 1.6-fold higher than 10°C, and the intensity of this particle size being nearly
1.7-fold higher that of the un-transitioned protein in samples at 10°C and 30°C. The progression
of transitioning, with temperature rising at a neutral pH, can be seen quite clearly through peak
shifts and elevated intensity in Figure 8 A-C. To show the effect of highly charged ELP-fusion
proteins, Figure 8 A-C is DLS data for PMPD2-L10Flag-APPIP in a neutral buffer. Here in Figure
9A it can be seen that PMPD2-L10F-APPIP particle sizes at a a low temperature of 10°C, at their
largest are 160 nm in size with a low intensity value of 15. When temperatures are increased, to
37°C and then 40°C in Figure 9B-C many more peaks or species are observed, with very low
intensity, suggesting transitioning is being hindered and ultimately will not occur when compared
to the results seen in L10Flag in a neutral buffer. This observation alludes to the fact that
transitioning is occurring, but hindered, and to a very small degree (particle sizes as low as 45 nm,
Figure 8C.) and in accordance with microscopy in Figure 7B where smaller particles are observed.
In contrast, PMPD2-L10Flag-APPIP in a buffer at its pI, displays a large degree of transitioning
(like that of unhindered L10Flag), which can be seen in Figure 10A-C when temperature is
increased from 10°C to 37°C then 40°C. In Figure 10A-B, a peak shift from 122 nm to 459 nm
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with 1.6-fold greater frequency observed when comparing PMPD2-L10Flag-APPIP at 10°C
versus 37°C. Then from 37°C to 40°C, in Figure 10B-C, a further shift is observed with most
particle sizes for PMPD2-L10Flag-APPIP at its pI near 531 nm with one major species. This result
is like that of the unhindered L10Flag in Figure 8 A-C. The latter confirms the effect and utility
of pI-BPS on ELP-based fusion molecules with highly charged ends, to both purify a practical
quantity and study the transitioning impedance in an application site at a neutral pH.
Here in these DLS experiments there could be a source of error that may affect a strict
reproducibility of data. The DLS machine utilized in these experiments has a internal mechanism
for warming the sample to a set point temperature. Uneven heating throughout the sample will
affect transitioning through a section of the sample where particle size is measured. A temperature
gradient through the sample could possibly cause the sample to transition unevenly resulting in
particle size differences between the similar experiments. Temperature was probed, separate from
the machine’s temperature measurement to aid in diminishing the amount of variance due to the
possibility of uneven heating.
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A.

B.

C.

Figure 8. Dynamic Light Scattering Data for L10Flag at a 7.4 pH, from 10°C to 30°C. L10Flag
at a neutral pH over temperatures A) 10°C, B) 30°C, and C) 37°C.
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A.

B.

C.

Figure 9. Dynamic Light Scattering Data for PMPD2-L10Flag-APPIP at a 7.4 pH, from 10°C to
40°C. A) PMPD2-L10Flag-APPIP a neutral pH over temperatures A) 10°C, B) 37°C, and C)
40°C.
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A.

B.

C.

Figure 10. Dynamic Light Scattering Data for PMPD2-L10Flag-APPIP at its pI, 4.1 pH, from
10°C to 40°C. PMPD2-L10Flag-APPIP at its pI over temperatures A) 10°C, B) 37°C, and C)
40°C.
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3.6 Implementation of a Matrix-Tethering ELP Fusion Protein
From the results of both the absorbance and DLS experiments for the evaluation of pH
dependent phase separation, the feature of using ELP fusion proteins for sustained presence in the
application site is inherently lost for fusion proteins with a high degree of hindrance of selfassembly due to charge. To implement a fail-safe method of sustaining fusion protein presence in
the application site and around ECM components that require protection from proteolytic
degradation, a fusion protein consisting of placental growth factor 2 (PlGF2) and a free ELP end
was constructed to perform the duty of tethering PMPD2-L10Flag-APPIP. The free ELP end
inherently interacts with the ELP portion of PMPD2-L10Flag-APPIP. While the PlGF2 end
interacts and binds to extracellular matrix components essentially tethering the dual inhibitor to
the wound bed. An experiment was ran where 1 mg/mL samples of L10Flag-PlGF2 were incubated
at 42°C for 10 minutes, to transition with collagen, fibrinogen, or alone. Then each sample was
centrifuged at 15,000 rpm for 5 minutes. The supernatant was discarded and the resulting pellet
was resuspended in 500 μl of 1xPBS. A 6 μl sample was taken from each resulting suspension,
and a total protein stain was performed on an SDS-Page gel and stained with simply safe blue
(Coomassie G250), and gel pictures were taken and analyzed. Figure 11 displays a total protein
staining result of the interaction of PlGF2 with fibrinogen and collagen. Here it is observed, in
lanes 3-5, that L10Flag-PlGF2 has affinity for, and under centrifugation, pulls fibrinogen and
collagen out of solution when heated and self-assembled. When compared to a single fusion of
PMPD2-L10Flag in lanes 7-9, it is observed that L10Flag or PMPD2 may have some affinity for
collagen already, but no affinity for fibrinogen. Whereas with L10Flag-PlGF2 affinity for
fibrinogen is observed in lane 5.
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Lane Key
1: Ladder
2: Collagen
3: Fibrinogen
4: L10F-PlGF2
5: L10F-PlGF2 +
Collagen
6: L10F-PlGF2 +
Fibrinogen
7: PMPD2-L10F
8: PMPD2-L10F +
Collagen
9: PMPD2-L10F +
Fibrinogen

Lane 1

2

3

4

5

6
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8

9

Figure 11. A Total Protein Stain of Samples of L10Flag-PlGF2 and PMPD2-L10Flag for the
Evaluation of Affinity of PlGF2 for Various Matrix Proteins.
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Chapter 4: Dual Inhibitory Activity of PMPD2-L10Flag-APPIP of
Elastase and Matrix Metalloproteinase-21
PMPD2-L10Flag-APPIP was designed for dual inhibitory activity against two proteases
found in high levels in chronic wounds, Neutrophil Elastase (NE) and matrix metalloproteinase-2
(MMP2). After the successful construction, synthesis, and purification of the dual protease
inhibitor, assays to screen the protein’s ability to block the activity of NE and MMP2 were
employed. Colorimetric drug discovery kits from Enzo Life Sciences Inc. and their accompanying
protocols were utilized to evaluate and determine the protein’s inhibitory activity.
4.1 Methods for the Determination of PMPD2-L10Flag-APPIP’s NE Inhibitory Activity
Utilizing the neutrophil elastase colorimetric drug discovery kit, the assay was performed
in a 96-well plate and OD412 read in a BioTek Synergy HT microplate reader. The two main
components of this kit are neutrophil elastase and its substrate, which when cleaved creates a
colorimetric product. Table 3 is a reference for the sample groups and their components in this
experiment. All groups in this assay were prepared by adding and mixing all the components,
besides the substrate. Then the plate was warmed to 37°C and the substrate was added to each
well, besides the blank wells. All samples were ran in triplicate. The negative control contained
NE, its substrate, and assay buffer. PMPD2-L10Flag-APPIP, and both single fusions, PMPD2L10Flag and APPIP-L10Flag were tested for inhibition of NE activity at protein concentrations
5x10-7, 5x10-6, 1x10-5, and 5x10-5 μg/μl. Additionally, fusion protein blanks in triplicate were

1

Information used in Chapter 4 has been previously published in Biotechnology Progress. Strauss, G. & Koria, P.
Hybrid fusion protein as a dual protease inhibitor for the healing of chronic wounds. Biotechnology Progress 37,
e3209 (2021). Permissions included in Appendix B.
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added to the plate since the experiment is ran at 37°C and protein transitioning will add to
absorbance measurements. The reading was performed as a kinetic assay at a constant temperature
of 37°C, over a 20-minute time interval, measuring OD412 every minute. The absorbance from
buffer and protein blanks were subtracted from the absorbance of corresponding sample groups
and control during analysis to obtain true absorbance of the cleaved substrate product. The slope
of the developed curves normalized to the slope of the control from collected absorbance over time
data were utilized to calculate % NE inhibition employing Equation 1.
Table 3. Experiment groups of the colorimetric NE inhibition assay and their respective
components
Sample Group
Components
Blank
Assay Buffer
Control
Assay Buffer + NE + Substrate
PMPD2-L1Flag-APPIP
Assay Buffer + NE +Substrate + Dual
Inhibitor at various concentrations
PMPD2-L10Flag
Assay Buffer + NE +Substrate + NE Inhibitor
at various concentrations
APPIP-L10Flag
Assay Buffer + NE +Substrate + MMP2
Inhibitor at various concentrations
Blanks for protein experimental groups
Assay Buffer + Inhibitor at various
concentrations

% 𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 = (1 −

𝑆𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙
𝑆𝑛𝑒𝑔.𝑐𝑜𝑛𝑡𝑟𝑜𝑙

) 100% (Equation 1)

4.2 Methods for the Determination of PMPD2-L10Flag-APPIP’s MMP2 Inhibitory Activity
Utilizing the MMP2 colorimetric drug discovery kit, the assay was performed in a 96-well
plate and OD412 read in a BioTek Synergy HT microplate reader. The two main components of
this kit are MMP2 and its substrate, which when cleaved creates a colorimetric product. Table 3 is
a reference for the sample groups and their components in this experiment. All groups in this assay
were prepared by adding and mixing all the components, besides the substrate, first. Then the plate
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was warmed to 37°C and the substrate was added to each well, besides the blank wells and a kinetic
absorbance reading was taken. All samples were ran in triplicate. The negative control contained
MMP2, its substrate, and assay buffer. PMPD2-L10Flag-APPIP, and both single fusions, PMPD2L10Flag and APPIP-L10Flag

were tested for inhibition of MMP2 activity at protein

concentrations 0.004, 0.008, 0.01, 0.05, 0.2, and 0.5 μg/μl.. Furthermore, fusion protein blanks, in
triplicate, were added to the plate since the experiment is ran at 37°C and protein transitioning will
add to absorbance measurements. The reading was performed as a kinetic assay at a constant
temperature of 37°C, over a 20-minute time interval, measuring OD412 every minute. The
absorbance from buffer and protein blanks were subtracted from the absorbance of corresponding
sample groups and control during analysis to obtain true absorbance of the cleaved substrate
product. The slope of the developed curves normalized to the slope of the control from collected
absorbance over time data were utilized to calculate % MMP2 inhibition employing Equation 1.

Table 4. Experiment groups of the colorimetric MMP2 inhibition assay and their respective
components.
Sample Group
Components
Blank
Assay Buffer
Control
Assay Buffer + MMP2 + Substrate
PMPD2-L1Flag-APPIP
Assay Buffer + MMP2 +Substrate + Dual
Inhibitor at various concentrations
PMPD2-L10Flag
Assay Buffer + MMP2 +Substrate + NE
Inhibitor at various concentrations
APPIP-L10Flag
Assay Buffer + MMP2 +Substrate + MMP2
Inhibitor at various concentrations
Blanks for protein experimental groups
Assay Buffer + Inhibitor at various
concentrations
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4.3 NE Inhibitory Activity of PMPD2-L10Flag-APPIP
Through the colorimetric kinetic assay for the evaluation of NE inhibition, inhibitory
activity of PMPD2-L10Flag-APPIP was confirmed and quantified as previously reported by the
author13. Figure 12 shows the inhibition of NE by the dual fusion protein. Utilizing the slope of
the curve for each tested concentration and the negative control, Equation 1 was used to calculate
% inhibition. In Figure 12 it can be observed that the dual fusion protein, when compared to the
control had near zero inhibition at a concentration of 5x10-7 μg/μl, and full inhibition at an inhibitor
concentration of 5x10-4 μg/μl. Through further analysis, 50% inhibitory concentration (IC50) was
calculated by plotting the % inhibition versus inhibitor concentration (Figure 13) and fitting the
curve to produce an equation for the trend. The calculated IC50 for NE by the dual inhibitor was
8.5x10-7 μg/μl.

Figure 12. A Kinetic Absorbance Analysis for Concentrations of PMPD2-L10Flag-APPIP and its
Inhibition of NE in the NE Colorimetric Assay.
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Figure 13. A Display of NE Inhibition, in % Inhibition, by the Dual Inhibitor, and the Single
Fusions.
4.3.1 NE Inhibitory Activity of PMPD2-L10Flag-APPIP Compared to the Single Fusions
From the colorimetric assay for NE inhibition, single fusions, PMPD2-L10Flag and
APPIP-L10Flag were tested for NE inhibition as previously reported13. Figure 14 A & B displays
the absorbance produced throughout the kinetic assay for the single fusions and their tested
concentrations for inhibition of NE cleaving the corresponding colorimetric substrate. In Figure
14A, it is observed that from a low concentration of 5x10-5 μg/μl showing little inhibition when
compared to the absorbance seen from the negative control. On the contrary, Figure 13B that
APPIP-L10Flag is not very effective at blocking NE.
From produced percent inhibition curves and their trend line equations (Figure 13) %
inhibition of each single inhibitor is displayed and utilized to calculate percent inhibition and IC
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50. IC50 for NE inhibition by PMPD2-L10Flag was calculated and estimated to be at a protein
concentration of 7.08x10-6 μg/μl. In contrast, inhibition of NE by APPIP-L10Flag levels off at
around 10% inhibition of NE at the highest tested concentration.
In comparison, PMPD2-L10Flag-APPIP and PMPD2-L10Flag had a similar IC50 of
8.5x10-7 μg/μl and 7.08x10-6 μg/μl, respectively. With an IC50 for NE inhibition by the dual
inhibitor being similar but lower than the single fusion, PMPD2-L10Flag, it can be concluded that
the dual fusion effectively inhibits NE when compared to the single fusion PMPD2-L10Flag.
However, though similar, there is nearly a 10-fold difference in IC50 between the dual and single
fusion for NE inhibition, with the dual inhibitor having the lower estimated IC50. This can likely
be attributed to the fact that the single fusion, APPIP-L10Flag, showed some quantifiable
inhibitory power against NE suggesting that the dual inhibitor and each bioactive end may have
the potential to act simultaneously and, in some cases, containing non-specific protease inhibition.
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A.

B.

Figure 14. A Kinetic Absorbance Analysis for Concentrations of the Single Fusions, A) PMPD2L10Flag and B) L10Flag-APPIP and Their Inhibition of NE in the NE Colorimetric Assay.
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4.4 MMP2 Inhibitory Activity of PMPD2-L10Flag-APPIP
From the colorimetric kinetic assay for the quantification of MMP2 inhibition, inhibitory
activity of PMPD2-L10Flag-APPIP was confirmed as previously reported by the author13. Figure
15 shows the inhibition of MMP2 by the dual fusion protein. Utilizing the slope of the curve for
each tested concentration and the negative control, Equation 1 was used to calculate % MMP2
inhibition. Here in Figure 15 it can be observed that the dual fusion protein, when compared to the
control had near zero inhibition at the lowest tested concentration of 0.004 μg/μl, and near full
inhibition at an inhibitor concentration of 0.5 μg/μl where it is seen that the slope of the absorbance
over time is close to 0. Through further analysis 50% inhibitory concentration (IC50) was
calculated by plotting the % inhibition versus inhibitor concentration (Figure 16) and fitting the
curve to produce an equation for the trend. The calculated IC50 for MMP2, inhibited by the dual
inhibitor was 0.04 μg/μl.
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Figure 15. A Kinetic Absorbance Analysis for Concentrations of PMPD2-L10Flag-APPIP and its
Inhibition of MMP2 in the MMP2 Colorimetric Assay.
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Figure 16. A Display of MMP2 Inhibition, in % Inhibition, by the Dual Inhibitor, and the Single
Fusions.

4.4.1 MMP2 Inhibitory Activity of PMPD2-L10Flag-APPIP Compared to the Single Fusions
Gained from the colorimetric assay for MMP2 inhibition, single fusions, PMPD2-L10Flag
and APPIP-L10Flag were tested for MMP2 inhibition as previously reported13. Figure 17 A & B
displays the absorbance produced throughout the kinetic assay for the single fusions and their
tested concentrations for inhibition of NE cleaving the corresponding colorimetric substrate. In
Figure 17A, it is observed that from a low APPIP-L10Flag concentration of 5x10-5 μg/μl showing
little inhibition, like the negative control, to a highest tested concentration of 0.5 μg/μl with near
complete inhibition. On the contrary, in Figure 17B, PMPD2-L10Flag is not nearly as effective at
blocking MMP2 as the single fusion, APPIP-L10Flag.
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From produced percent inhibition curves and their trend line equations (Figure 15) %
inhibition of each single inhibitor is displayed and utilized to calculate percent inhibition and IC
50. IC50 for MMP2 inhibition by APPIP-L10Flag was calculated and estimated to be at a protein
concentration of 0.05 μg/μl. In contrast, inhibition of NE by APPIP-L10Flag levels off at around
20% inhibition of NE at the highest tested concentration.
In comparison, PMPD2-L10Flag-APPIP and APPIP-L10Flag had a similar IC50 of 0.04
μg/μl and 0.05 μg/μl, respectively. This result concludes that the dual fusion made to create
PMPD2-L10Flag-APPIP does not negatively affect the inhibitory capabilities in the application of
this dual protease inhibitor when compared to a single fused inhibitor, APPIP-L10Flag, for MMP2
inhibition.
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A.

B.

Figure 17. A Kinetic Absorbance Analysis for Concentrations of the Single Fusions, A) PMPD2L10Flag and B) L10Flag-APPIP and Their Inhibition of MMP2 in the MMP2 Colorimetric Assay.
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4.5 Dual and Simultaneous Inhibition of NE and MMP2
Additional to the standard screening for PMPD2-L10Flag-APPIP inhibition of NE and
MMP2, an experiment was run to evaluate the protein’s ability to bind and block NE and MMP2
concurrently. The experiment was run in accordance with the MMP2 and NE colorimetric drug
discovery kits from Enzo Life Sciences Inc. However, this experiment was run in both the presence
of NE and MMP2, rather than separate experiments as previously described. In this case two
controls were made, one that just contained assay buffer, NE, and substrate, and the other with
assay buffer, NE, MMP2, and substrate. Two experimental groups were formed: the first with
assay buffer, NE, substrate, and the dual inhibitor; while the other with assay, buffer, NE, MMP2,
substrate, and the dual inhibitor. Both experimental groups contained the dual inhibitor at a
concentration of 0.05 μg/μl. Figure 18 displays clearly that in the negative control containing just
1 protease, NE, chewed up the substrate as indicated by the slope of the absorbance curve. The
negative control that contained two proteases, NE and MMP2, further chewed up the existing
substrate elevating the slope even further. Also in Figure 18, are the results of the experimental
groups with the dual inhibitor. Both the experimental groups showed inhibition to a similar level
as indicated by similar slopes of their respective absorbance curves in comparison to the controls.
This result confirms PMPD2-L10Flag-APPIP’s ability to block both NE and MMP simultaneously
and effectively.
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Figure 18. The Simultaneous Activity of Each Bioactive End of PMPD2-L10Flag-APPIP in a
Kinetic Inhibition Assay Containing MMP2 and NE.

4.6 Statistics and Sources of Error in the Inhibition Experiments
Standard deviation of the average absorbance is applied to the graphs of inhibition. Possible
sources of error are rooted in the transitioning properties of the ELP-based inhibitors. Since the
ELP-fusion proteins may transition at the 37°C experiment parameter, ELP-fusion protein blank
samples were added to the experiment to account for transitioning that may add to the absorbance
of the colorimetric measurement. This could be a possible source of error propagation as the degree
of transitioning is highly dependent on the accuracy of inhibitor concentration in both the
experimental and blank wells.
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Chapter 5: Mesenchymal Stem Cells and Their Ability to Condition Media Into a
Potent Proliferation Inducing Cocktail
Human Mesenchymal Stem Cells (MSCs) have been widely used in numerous ways to
treat a variety of diseases. Most notably, mesenchymal stem cells harvested from the umbilical
cord, bone, amniotic fluid, and adipose tissue23 have commonly been used as a cellular-based
therapy for the treatment of diseases that cause tissue degeneration or debilitating tissue damage.
Their attractiveness for cellular therapy is wide spread, where they are utilized as a whole cell for
their multi- and pluripotency that in theory lend them useful in application in the body to seed new
cells of the damaged tissue type23-25. Furthermore, their application has gone as far as to suggest a
usefulness of the products contained inside of extracellular vesicles produced and secreted by
MSC’s25. With many application styles of MSCs and their products they produce, the commonality
in their use is the pursuit of promoting tissue healing. Whether that is through the delivery of the
pluripotent cell with the capacity for differentiation23-25, the immunomodulatory and antiinflammatory qualities of MSCs23, 26, or for the various regenerative biproducts that MSCs produce
to influence cellular migration, growth, and protein deposition for complete tissue repair22.
Regarding cellular biproducts created by MSCs, this has been previously studied to some
degree where it was determined that conditioning biproducts of MSCs include some very
prominent wound healing peptides such as EGF, TGFa, TGFb1, VEGF, FGF2, as well as many
immunosuppressing and modulating proteins22. Wound healing and tissue regeneration rely on a
lot of these growth factors and peptides in natural tissue healing processes. Vascular endothelial
growth factor (VEGF) is important to stimulate remodeling processes like cellular migration and
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proliferation27. Endothelial growth factor (EGF) is important for stimulating re-epithelialization of
a wound, while transforming growth factors such as TGFb1 and TGFa aid in re-epithelialization
but also in matrix formation and remodeling of the wound17 which is important for regaining
structural integrity in newly healed or formed tissue. Similarly, Fibroblast Growth Factor 2 (FGF
2) helps aid in the remodeling and matrix formation process17. Growth factors such as EGF, TGFa,
TGFb1, FGF2, and VEGF have all been found to increase in levels in a naturally healing acute
wound with no therapeutic intervention, but have been seen in decreased levels in chronic
wounds17.
Here it is proposed that due to current knowledge of chronic wounds and that there are
growth factor species whose levels can be correlated with an acute healing wound versus a chronic
wound17, it is advantageous to replace the growth factors that are seen in suppressed levels in
chronic wounds to move the wound to closure. As previously drawn, there is a correlation, between
the proteins needed in wound healing, and those that have been found to be produced by
mesenchymal stem cells. Therefore, a great candidate for proliferation inducing therapies to aid in
the remodeling of hard-to-heal or chronic wounds, is media conditioned by stem cells, which
include proteins that are essential to cellular migration, proliferation, and remodeling of the
wounded tissue. A protein cocktail, from the conditioning of media, by mesenchymal stem cells
can easily be mixed with other protein-based therapeutics, such as the protease inhibitor described
here to create a self-protecting therapeutic to aid in the downregulation of protein destroying
proteases found in high levels in chronic wounds, while delivering and protecting present growth
factors necessary for tissue regeneration of the skin.
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5.1 Culturing of Mesenchymal Stem Cells
Human umbilical cord derived mesenchymal stem cells (um-MSCs) were obtained from
ATCC and plated in a 100 mm dish. The culture was expanded to confluency in 10 mL of basal
stem cell culture media, MesenPRO RS (GibcoTM), and supplemented with 2% stem-cell qualified
FBS. The cells were maintained at 37°C and 5% CO2. The MSCs were passed when 80%
confluency was reached, utilizing 0.25 trypsin-EDTA, and sub-cultured in 100 mm dishes. It was
observed that um-MSC subcultures would expand at a steady rate out to 5 to 6 passages (changing
media every 2 days, reaching confluency and passing every 5 to 7 days). Upon media collection
and media replacement, 2 mL of media from the last 48-hour incubation was reserved in the dish,
and 8 mL of new media was added. Around passage 5, proliferation would slow down and the
MSCs would stay at around a 70-80% confluency, without cell death if maintained by the described
media replacement every 48-hours.
5.1.1 Harvesting Um-MSC Conditioned Media
Throughout the expansion process of these um-MSC’s, during media replacement (every
48 hours) the media was collected from a MSC culture that was near 70 to 80% confluency and
stored to be screened for proliferative effects in vitro. However, it was observed that when the umMSCs, themselves, slowed down in proliferation they still maintained healthy cellular morphology
and attachment. So, a sub-culture of passage 5 um-MSC’s were maintained in this state where the
MSCs were live and healthy, but not dividing at a steady rate wouldn’t lead to another sub-culture.
Every 48 hours the media was replaced, and the old media collected and stored at -20°C. In some
cases, these slow growing cultures could be maintained for weeks to well over a month while
collecting a potent conditioned media, without death of the MSCs.
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5.1.2 Processing the Um-MSC Conditioned Media
Before use of the MSC conditioned media, all samples to be screened were thawed and
filtered with a 0.22 μm filter to result in an acellular product, just containing free proteins and
soluble small molecules that will remain after filtration. In some cases, the conditioned media was
applied in vitro as a liquid to test for its ability to cause proliferation, while in other cases it was
freeze dried through lyophilization and applied as a dry product. Additionally, in some
experiments, filter paper was soaked in conditioned media, frozen, and then lyophilized to embed
the conditioning products within a solid medium.
5.1.3 Verification of Um-MSCs
Flow cytometry was employed to verify the mesenchymal stem cells using criteria of cell
surface markers to characterize human derived MSCs. MSCs are characterized as positive for
CD73, CD90, and CD105 cell surface markers28. Furthermore, MSC characterization guidelines
require them to be negative for the cell surface markers CD14, CD34, and CD4528. Conjugated
antibodies for CD73, CD90, and CD105 were obtained and to be utilized with florescent flow
cytometry channels for excitation and emission of FITC, thy-1 phycoerythrin, and allophycocyanin
respectively. While the negative markers were identified with human Alexa Flour 405 conjugated
human antibodies, the same channel as DAPI. DAPI was used in a fully stained sample of MSCs
to evaluate viability. A fully stained sample without DAPI added was evaluated for negative
marker expression. All negative and positive antibodies were added to a dilute sample of UmMSCs and analyzed for positive and negative marker expression. To acquire negative marker
expression a comparison must be made between a fully-stained sample with DAPI, and a fully
stained without the addition of DAPI. Figure 19 displays the progression of analysis and
identification of um-MSC’s through the staining of the positive markers CD73, CD90, and CD105
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with differing conjugates, as well as DAPI to determine viability of the sample. As it can be seen
from the data reported in Figure 19, cells containing the CD73 positive marker have been identified
and exist on the surface of 100% of the live, parent population that expresses both CD90 and 105,
with 84% of all live cells detected are positive for all three markers. Figure 20 displays the flow
cytometry results of a fully stained sample without DAPI, but still acquiring measurements
utilizing the DAPI

channel, for the isolation of cells that may present negative markers

disqualifying them as MSCs. In Figure 20 it is observed that there is no negative marker
expression. These results validate the use of these cells as MSCs for conditioning of media.
Furthermore, this sample contained a 74% viability post isolation and staining for flow cytometry.
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Figure 19. Flow Cytometry Results of Um-MSC’s Targeting the Expression of Each Positive
Marker for Mesenchymal Stem Cell Determination.
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Negative
Markers

Figure 20. Flow Cytometry Results of Fully Stained Cells Without DAPI to Determine the Degree
of Negative Marker Expression.
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5.2 Screening Um-MSC Conditioned Media for Inducing Cellular Proliferation
C2C12, a mouse muscle myogenic cell line from ATCC was obtained. C2C12 cells have
shown quick responsiveness to growth factor induced proliferation and growth as previously used
by this laboratory29. C2C12 cells were removed from liquid nitrogen storage and seeded at a
density of 106 cells per 100 mm dish. The cells were maintained in DMEM 10% FBS supplemented
with 1% antibiotic-antimycotic (AA) at 37°C and 5% CO2. The C2C12 cells expanded to 80%
confluency were then passed to 24-well plates, at a seeding density of 5x104 cells per well, for
treatment with MSC conditioned media product.
5.2.1 Proliferation Experiments Utilizing C2C12 Cells in a Serum-Free Environment
C2C12 cells were plated at a seeding density of 5x104 cells per well and incubated at
standard culturing conditions (37°C and 5% CO2) over night for attachment. After attachment, the
cells in each well were washed three time in 1xPBS, and after the last wash, serum-free DMEM
1% AA was added to each control (n=12) and experimental well (n=12). Then, 0.2 mL of serumfree MesenPRO RS was added to each control well for a final volume of 0.4 mL. MSC conditioned
media (200 μl) was then added to each experimental well (n=12), for each conditioned media
sample) on the 24-well plate for a total and final volume of 0.4 mL in each well. The assay plate
with control wells and treatment wells was then incubated under standard cell culture conditions
for 72 hours.
Following the incubation period, the cells were washed three times in 1xPBS and after the
last wash 200 μl of deionized water was added to each assay well. Then, a Hoechst assay was
employed by utilizing three freeze-thaw procedures to lyse the cells. A 100 μl sample of the lysate
was taken from each well and transferred to a corresponding well on a 96-well, round bottom,
assay plate. Hoechst 33342, at a working concentration of 0.002 mg/mL was added 1:1 with each
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lysate sample, with a final volume of 200 µl in each well to be analyzed on the 96-well plate. The
assay was then read, Ex/Em 360/460, after a 30 second shaking procedure on a BioTek Synergy
HT microplate reader. The resulting data was blanked and analyzed by comparing the degree of
florescence, which corresponds to the number of cells in each well, compared to that of the control
wells. The average florescent results of the conditioned media treatment wells were divided by the
average florescence of the control wells, and multiplied by 100%, to normalize the results to that
of the control, and display % growth.
5.2.2 Proliferation Experiments Utilizing C2C12 Cells Treated with MSC-CM and NE
The proliferation experiment using um-MSC conditioned media to induce proliferation,
was employed again, but with levels of protease added to the treatment to visualize the affect
proteases have on the conditioned media protein products that will fall victim to the inherent threat
of proteolytic degradation seen in hard-to-heal wounds. After plating C2C12 cells in a 24-well
plate and allowing for overnight attachment in standard cell culture conditions, all wells were
washed three times in 1xPBS. Immediately after aspirating the last washing procedure, serum free
DMEM with 1% AA was added to each control and experimental well. Utilizing the same
conditioned media sample, 0.2 mL of processed conditioned media was added to each treatment
well for a total final volume of 0.4 mL. While the control wells (n=6) received 0.2 mL of serumfree MesenPRO RS media. One group of conditioned media treated wells were left unexposed to
protease, while other well groups (n=6) received various concentrations of elastase with the largest
concentration of elastase being 200 mU/mL, a clinically relevant level of protease18, to see the true
degrading affect that protease levels have on the potential use of conditioned media products in
chronic or hard-to-heal wounds. The elastase concentrations tested were 0.02, 0.2, 2, 20, and 200
mU/mL.
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After treatment, the 24-well plate was incubated under standard cell culture conditions for
72-hours and then a Hoechst assay was utilized to analyze the proliferative effects of the
conditioned media in the presence of protease. The Hoechst assay was performed and analyzed in
accordance with the protocol described in section 5.2.1.
5.3 Induction of Proliferation of C2C12 Cells Treated with Um-MSC Conditioned Media
With or Without the Presence of Proteases
Umbilical cord derived MSC conditioned media obtained from the harvesting of the used
media from MSC’s in section 5.1.1 was used to induce proliferation in C2C12 mouse myogenic
cells in vitro. Figure 21 displays the experimentation with various samples from different
collections of um-MSC conditioned media. Here, it is observed that samples such as MSC 1 and
MSC 4 induced a 4.8-fold increase in cellular proliferation when compared to the untreated
control. MSC 3 in Figure 21, caused the least amount of proliferation, but was still 3.6-fold higher
proliferation than that of the untreated control.
Figure 22 displays the results of a proliferation assay with C2C12 cells treated with
conditioned media, and various concentrations of NE. Um-MSC conditioned media sample MSC
3 from the experiment results reported in Figure 21 was the sample used for treatment with the
various concentrations of NE and showed similar induction of proliferation, in Figure 22 when
NE=0 mU/mL. This is important to note as it expresses the consistency in capturing proliferation
induction using this assay. Though, in Figure 22 when analyzing the effect of NE on conditioned
media treatments, it is seen that at 200 mU/mL of NE there is a significant decrease in C2C12
proliferation, but as the concentration of NE is lessened, proliferation steadily increases back to
the degree of proliferation observed in the MSC conditioned media treatment with no NE. In Figure
22, there is a 1.6, 1.14, and 1.1-fold decrease in proliferation, for 200, 20 and 2 mU/mL
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concentrations of NE respectively, compared to cells that were treated with just MSC conditioned
media. At an NE concentration of 0.2 and 0.02 mU/mL it is observed that proliferation is that of
the C2C12 cells that were treated with just MSC conditioned media, no inhibitor. The latter result
drives the importance in combining the dual protease inhibitor with um-MSC conditioned media
Figure 23 displays the proliferation results when utilizing MSC conditioned media in dry
forms in vitro. As it is observed in Figure 23, all dry processed um-MSC conditioned media caused
proliferation over that of the untreated control. The MSC conditioned media embedded filter paper
had a 1.44-fold increase in proliferation over the degree of proliferation of untreated control. While
lyophilized products that were dialyzed, or not, and used in powder form showed a 2.98 and 3.50fold increase in proliferation. These results align closely with liquid-based treatments, except for
the filter paper embedding of MSC conditioned powder and the deviation here is due to the fact
that there is volume limitations for embedding the powder within a thin piece of material.
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Figure 21. The Proliferation of C2C12 Cells Treated with Various Collections of Um-MSC
Conditioned Media.*Statistically significant compared to an untreated control with p≤0.05 and
Fcrit≤F.
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Figure 22. The Degradation of MSC Conditioned Products by Various Concentrations of NE.
Elastase Concentrations: 200, 20, 2, 0.2, 0.02 mU/mL. *Statistical significant when compared to
sample MSC-CM/0 NE, p≤0.05 and Fcrit≤F.
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Figure 23. Um-MSC Conditioned Media in Various Treatment Forms Tested for Inducing
Proliferation of C2C12 Cells. *Statistically significant with p≤0.05 and Fcrit≤F when compared to
the untreated control.

5.4 Statistical Analysis for the Proliferation Assays
From all proliferation experiments standard deviation from the average fluorescence from
Hoechst assays for each sample was calculated, and % standard deviation was applied to each
graphical representation of the data. Additionally, a single factor Anova (p≤0.05) was performed
from the data for each experimental MSC-CM treatment group and compared to the control (Figure
21 & 23). For comparisons between MSC conditioned media groups to their respective untreated
control the P-value was p≤0.05 with F≥F-crit for all MSC conditioned media treatments. For
Figure 22 the single factor Anova was performed between the data from the differing
concentrations of NE to the wells that received 0 mU/mL NE, where p≤0.05, F≥F-crit.

59

Chapter 6: An Essential Combination of Protease Inhibition with the
Delivery of a Um-MSC Conditioned Media
From in vitro investigation, and prior work by the author and laboratory13, 18, it is observed
as essential to protect any growth factor therapies for healing HtHWs through an accompanying
treatment of protease inhibition. Growth factors have been a target therapy for healing chronic
wounds7, 30, 31, including the use of stem cell-based products32. However, it is observed that not
much research has yet translated into mainstream use in clinical settings, while still today
remaining a large topic in the conversation of healing wounds faster. Whether it be the limited
efficacy of basic growth factor combinations strained by proteolytic degradation, or limited means
of funding for translation, there exists a clear need for a therapy with high efficacy and that can be
produced on a large scale at low costs while also minimizing wound care tasks for the clinician.
All of these needs can be answered utilizing the right protein combinations to create a growth
factor cocktail that is both highly potent and self-protecting to elevate the usefulness of the
treatment.
In past work done by this author13 and laboratory18, the main focus was on creating
recombinant proteins such as recombinant growth factors to be combined with recombinant
protease inhibitors for inhibition. Despite ease in plasmid expression and purification, utilizing
recombinant processes and ITC, there exists a need for a simpler and cost-effective way to produce
a growth factor cocktail with all of the essential proteins. Here it is described that a combination
of the dual protease inhibitor, and a um-MSC conditioned media containing growth factors can be
protected and delivered to heal HtHWs.
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6.1 The Proteolytic Degradation of Therapeutic Proteins
As previously described by the author13, a simple experiment was employed to observe the
direct effect of proteolytic degradation of growth factors, in vitro, in the presence of proteases. A
recombinant keratinocyte growth factor, rhKGF, was incubated in the presences of either NE or
MMP2. NE and MMP 2 were added to samples with or without the dual protease inhibitor,
PMPD2-L10Flag-APPIP. Each sample was incubated for 24-hours, including a control that just
contained rhKGF. However, 2 hours and 4 hours after the start of the incubation a sample was
taken from each experimental group. After the last samples are collected at the end of the 24-hour
time point, a standard western blotting procedure was employed. An antibody specific to human
KGF was used to stain the protein containing membrane and the resulting image captured using
chemiluminescence.
6.1.1 The Protection of rhKGF from the Degradation Caused by NE and MMP22
Figure 24 is the western blot observing the protection of rhKGF from proteolytic
degradation using the dual protease inhibitor. Lane 1 is the biotinylated ladder, while lane two is
a control sample of rhKGF. Lanes 3-4 show the degradation of rhKGF when no inhibitor is present.
It is seen that in lanes 3 rhKGF is still present at the 2-hour mark while fully degraded in lanes 4
and 5, at the 4- and 24-hour time points respectively. When the protease is present, lanes 6-8,
rhKGF remains present through all time points. In lanes 9-11, it is seen that rhKGF is almost fully
degraded at the 24-hour mark by MMP2, while in lanes 12-14 the rhKGF is unaffected by MMP2
through all time points of the experiment. These results conclude that proteases indeed negatively
influence locally residing growth factors, where in this experiment rhKGF was degraded quickly

2

Information in Section 6.1 has previously been published in Biotechnology Progress. Strauss,
G. & Koria, P. Hybrid fusion protein as a dual protease inhibitor for the healing of chronic
wounds. Biotechnology Progress 37, e3209 (2021). Permissions in Appendix B.
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by NE, taking just 4 hours to destroy the rhKGF. Additionally, MMP2 had the same affect, but to
a lesser degree. These results also show the importance of the dual protease inhibitor for the
protection of rhKGF, where, when the dual inhibitor was present, the rhKGF remained for the
entirety of the 24-hour experiment.

Figure 24. A Western Blott Analyzing the Protection from Degradation of RhKGF in the Presence
of NE and MMP2 Over a 24-Hour Incubation.

6.2 A Chronic Wound Diabetic Mouse Model
A combination of um-MSC conditioned media and the dual protease inhibitor were tested
for wound healing capabilities, in vivo, in a diabetic chronic wound mouse model. The necessity
for this combination has been shown valuable in vitro, but it is imperative that this combination is
tested in a real wound environment. The animal model protocol run here, followed regulatory,
timeframe, and animal safety guidelines set out by the University of South Florida’s Institutional
Animal Care and Use Committee (IACUC) before, during, and after the animal experiment was
employed and the approval can be viewed in Appendix B of this manuscript. Nine diabetic mice
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were obtained from The Jackson Laboratory. All mice ordered and received from The Jackson
Laboratory were female and of the strain 000697, a B6.BKS(D)-Lepr db/ that were 6-8 weeks old.
Upon arrival the mice were left to acclimate for 7 days before a wounding procedure was
employed. Fourteen days after the initial therapeutic treatments, the mice were euthanized, and
tissue samples were collected from the wound of each mouse to evaluate whether reepithelization
and matrix deposition occurred when treated with the combination of PMPD2-L10Flag-APPIP
and um-MSC conditioned media.
6.2.1 A Surgical Wounding Procedure
After mice arrival and a 7-day acclimation period, the mice underwent the following
wounding procedure. One mouse at a time was anesthetized utilizing isoflurane and shaved on the
middle of the back of the mouse. Once shaved, if there was a large density of hair on the mouse,
Nair was utilized to make the back of the mouse bald in the area of incision. It is important to get
a clean shave to ensure a durable application of the bandages at the end of the wounding procedure.
Once cleanly shaved and sterilized with an alcohol pad, a 1 cm x 1 cm square, scored with a
permanent marker was applied. The incision was made utilizing 11.5 cm straight blade
Metzenbaum scissors to cut along the scored 1 cm x 1 cm square on the skin of the mouse. The
incision was started at a corner of the square by pulling up one corner with Graefe forceps and
making the initial cut with the skin tuff pulled off the back of the mouse, and then cutting along
the rest of the scoring lines. Once the 1 cm x 1 cm incision is made the resulting square piece of
skin was removed from the back of the mouse.
6.2.2 NE Pretreatment for Modeling and Inducing a Chronic Wound Environment
Nine mice were pretreated with NE for 7 days to model a chronic wound environment
before therapeutic treatments. Fractions of fibrinogen and thrombin were prepared to then mix to
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become a fibrin gel for the delivery of both NE and the therapeutic treatments. The fibrinogen
fraction was prepared by making a stock solution at a concentration of 62.5 mg/mL. The working
fibrinogen solution is achieved by diluting the stock 1:10 in 1xPBS. While the thrombin working
solution was made from the mixing of 50 μl of 100 U/mL solution of thrombin, 5 μl of 1 M CaCl2,
and 345 μl of deionized H2O. During wounding the thrombin fraction was placed on ice and the
fibrinogen fraction was placed in a 37°C water bath. When ready to apply a fibrin gel to the wound
on the back of the mouse, 20 μl of the thrombin fraction is combine with 80 μl of the fibrinogen
fraction and mixed. NE was added to the fibrin gel to a final NE concentration in the 100 μl gel of
250 mU/mL (a clinically relevant concentration in chronic wounds) and then applied to the wound
and let to solidify for 2 minutes. The mouse was then bandaged, removed from the isoflurane, and
observed until fully awake. This NE pretreatment for 9 mice was done twice in the 7-day
pretreatment period and then therapeutic treatments were employed.
6.2.3 Treating the Mice Wounds with Fibrin Gels Containing the Dual Protease Inhibitor and UmMSC Conditioned Media
Fibrin gel preparation here follows the procedure outlined in section 6.2.2, however
PMPD2-L10Flag-APPIP is added to the fibrinogen fraction for 3 mice receiving a full treatment
of both inhibitor and um-MSC conditioned media, with a final concentration of 1 μg/μl. Um-MSC
conditioned media was dialyzed, frozen, and lyophilized. The resulting powder was added into the
fibrinogen fraction at a concentration of 0.5 μg/μl, in accordance with the conditioned media
volume that showed results in the in vitro proliferation studies. Before treatment the thrombin
fraction was placed on ice, while the fibrinogen fraction containing um-MSC conditioned powder,
and the dual protease inhibitor was placed in a 37°C bath. The fibrin gel was made by adding 20
μl of the thrombin fraction to 80 μl of the fibrinogen/inhibitor/conditioned media fraction. Then it
64

was lightly mixed and NE was added to the gel for a final concentration of 250 mU/mL. Next, the
gel was added to the wound and let to solidify for 2 minutes. After the gel was solidified, bandages
were applied, and the mouse was observed until awakening from the anesthesia.

Table 5. Treatment groups and controls for the chronic wound mouse model.
Treatment Groups

Format
7-Day NE Pretreatment + Continuous NE Treatment

Negative Control
MSC-CM Treated

Full Treatment

7-Day NE Pretreatment + Continuous NE Treatment with
Um-MSC Conditioned Powder
7-Day NE Pretreatment + Continuous NE Treatment with
Um-MSC Conditioned Powder and the Dual Protease
Inhibitor

6.2.4 Tissue Collection and Histology
Fourteen days from the application of therapy, 21 days from NE pretreatment, the mice
were euthanized, and wound tissue was collected. The mice were euthanized using a CO2 flow rate
of 10%-30% of cage volume per minute and a secondary means of euthanizing was employed via
cervical dislocation. The wound tissues were collected after each mouse was euthanized, by cutting
around the wound, leaving a halo of healthy tissue, with Metzenbaum scissors and pulling the
entire circular wound off the back of each mouse. The wound was cut in half down the diameter
of the tissue sample. Half of the wound was placed in a specimen mold with OCT compound with
the wound edge placed down for tracking orientation for tissue sectioning. Immediately, the tissue
sample in the cryomold was placed on dry ice for flash freezing, and then stored in -80°C until
sectioning. The sectioning was performed by Moffit Cancer Center’s histology core. Tissue
samples were sectioned to obtain a full tissue section of the cross section of the wound. Trichrome
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stains were employed and analyzed in microscopy to evaluate the degree of healing through
identifiable features such as re-epithelialization and collagen matrix formation in the wound
samples.
6.3 Chronic Wound Mouse Model Results
Figure 25 shows representative images of 2 mice that were NE pretreated and was treated
continuously with NE throughout the experiment but did not receive a therapeutic treatment. While
Figure 26 displays mice that got pretreated and continuous treatment with NE, but at the start of
therapeutic treatments received um-MSC conditioned media and continued therapeutic treatment
throughout the experiment. Figure 27 displays mice that were pretreated and continuously treated
with NE, however this mice group received a full therapeutic treatment of both um- MSC
conditioned media and the dual inhibitor, PMPD2-L10Flag-APPIP.
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Figure 25. Representative Images of the Mice Wounds from the NE Pretreated Controls Taken at
the Experiments End Point.

Figure 26. Representative Images of the Mice Wounds from the Experimental Groups that were
NE Pretreated and then Received MSC Conditioned Media Treatments with Continuous NE
Treatments.

67

Figure 27. Representative Images of the Mice Wounds from the Experimental Groups that were
NE Pretreated and then Received MSC Conditioned Media and PMPD2-L10Flag-APP with
Continuous NE Treatments.
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6.3.1 An Analysis of Wound Epidermal Thickness and Collagen Composition
Tissue sections were stained with a Masson’s trichrome stain to evaluate the degree of
collagen composition and epidermal thickness of the center of each wound. Figure 28 A-C are
representative images of mice wound tissue sections that underwent trichrome staining and
pictures captured at 40x magnification. A qualitative analysis of these images show, in Figure 28
A-C, stained blue collagen strands between cell nuclei appearing light blue to gray in color with
the nuclei of cells staining a dark blue to purple in color. Figure 28 A-B are images of the untreated
control mouse wound and a mouse wound that was treated with just MSC-CM, respectively. When
comparing the images in Figure 28 A-B to Figure 28 C it is apparent that normal tissue anatomy
with visible layers of the skin are apparent in image C where a full therapeutic treatment of MSCCM and PMPD2-L10Flag-APPIP was delivered, while in A and B there is a less defined skin
anatomy.
ImageJ was utilized on the 40x microscopy images of trichrome staining of each tissue
section from each mouse group, a image from the center of the wound was taken at 40x
magnification, the scale was set in ImageJ to align with that of the scale of the 40x images. The
epidermis from each image was measured for thickness three separate times across the epidermis
of the tissue section to analyze epidermal thickness. The results from the epidermal thickness
analysis can be seen in Figure 29. A 2.8-fold greater epidermal thickness was observed in the full
treatment group over that of the untreated control mice. Furthermore, a 1.4-fold greater epidermal
thickness was observed in the full treatment group over that of the mice that were treated with just
MSC-CM. This result suggests that mice that received the full treatment, MSC-CM and PMPD2L10Flag-APPIP, healed to a greater degree than the untreated control mice and mice simply treated
with MSC-CM.
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Additionally, an ImageJ analysis of collagen composition of the trichrome stains further
confirms the more developed healing in the full treatment group. Figure 30 displays the results of
average collagen composition of all mice from each group (untreated, MSC-CM treated, and MSCCM plus the dual inhibitor) and their collagen composition of the wound 14 days following
therapeutic treatment. In Figure 30 it is observed that a 1.7-fold increase in collagen composition,
was achieved over the untreated control, observed by the full treatment group. However, the mice
group that only received MSC-CM displayed collagen composition in amounts like that of the
untreated control mice. Development of more collagen in the mice group that were treated with
both MSC-CM and the dual inhibitor further suggests that the untreated control mice and mice just
treated with MSC-CM are farther behind in healing than that of the full treatment group.
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Figure 28. Representative Images of Masson’s Trichrome Stained Wound Tissue Samples. Utilized for Collagen and Epidermal
Thickness Quantifications Where A) is a Sample from the Untreated Control, B) is from the Treatment with MSC-CM, and C) Received
the Full Treatment, MSC-CM and PMPD2-L10Flag-APPIP, Where the Dashed Line Represents the Basement Membrane, and E:
Epidermis, D: Dermis
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*

Figure 29. The Average Epidermal Thickness from Tissue Samples Collected from Each Mouse
Group Measured in ImageJ and Normalized to the Untreated Control. *Statistically significant
when compared to the untreated control group with p≤0.05 and Fcrit≤F.
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*

Figure 30. Collagen Composition of the Mice Wounds Normalized to the Collagen Composition
of the Untreated Control. *Statistically significant with p≤0.05 and Fcrit≤F.
6.3.2 Statistical Analysis of Mouse Model Results
A single-factor Anova was ran between groups (Untreated, MSC-CM treated, MSC-CM
and PMPD2-L10Flag-APPIP treated) for the ImageJ analysis of collagen composition. The
difference of collagen composition between the Untreated controls and the mice treated with MSCCM were statistically insignificant (P≥0.05, Fcrit≥F). This statistical result further confirms that
there is no difference between mice in this experiment that go untreated and mice that just receive
the treatment of MSC-CM and the null hypothesis cannot be rejected. In contrast, statistical
significance was found when comparing mice that were treated with both MSC-CM and the dual
inhibitor to mice that were untreated or treated with just MSC-CM. A single factor Anova was ran
and P-values≤0.05 were obtained with F-critical values less than the F-values. Meeting these two
criteria alludes to significant differences between the full treatment group, and the mice that were
untreated or treated MSC-CM.
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Chapter 7: Discussion
Chronic wounds and wounds with delayed healing have been on the forefront of costly
medical treatment for decades. Though delayed wound healing has traditionally affected those who
belong to elderly populations, the impact chronic wounds have on the healthcare system is
continually rising from an increase in prevalence of obesity related diseases in even middle-aged
populations1, 2. Given the association between chronic wounds and other diseases, it takes a wellrounded healthcare approach to prevent delayed wound healing. An all-encompassing approach to
prevention and elimination of disease in a patient that suffer from delayed healing is important,
but it does not necessarily address the root cause as to why a wound won’t heal. Immediately,
current chronic wounds would benefit from a therapeutic approach that simply focuses on closing
a wound through rebalancing tissue degradation and deposition, while focusing on preventing new
chronic wound formation on a patient through the advocacy of lifestyle changes and an immediate
pursuit of medical treatment when a patient with chronic wound history obtains a new wound.
Current treatments have focused on very important concepts like debridement to get rid of
unviable tissues and established infections7, 8. Practices such as debridement are very basic but
may be absolutely necessary to get back to a wound environment that is not overwhelmed with
dead tissues. However, some wounds may be so entirely halted in a phase of degradation, treatment
methods like debridement may not be effective at all for the interruption of this vicious cycle,
while needing to be employed repeatedly to eventually obtain positive results. Furthermore, it is
apparent through this research and related research13, 18, that protein based treatments, currently
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employed, will not survive the harsh wound environment in the presence of proteolytic degradation
without the use of protease inhibitors.
This dry, three-component, protein-based therapeutic for the treatment of hard-to-heal
wounds contains the functionalities necessary for restoring the balance between tissue degradation
and deposition while containing characteristics related to sustained delivery and control in the
application site. An expansion of research related to this protein cocktail include testing for its
efficacy for sustained release, its effectiveness in human wound healing, and further research into
application styles that may provide this therapeutic with the ability to treat any wound in any
environment. Additionally, regenerative medicine practices utilizing stem cell products have been
a prominent talking point for healing wounds and highly damaged tissue through the application
of allograft tissue. However, regenerative medicine products are underproved for their efficacy in
relation to delivering functional cells to injured tissue. Furthermore, most stem cell derived wound
healing products that contain live cells or solubilized proteins require unique and expensive storage
conditions (-80°C and liquid nitrogen) and are therefore limited in shelf life, shipping constraints,
and application styles. The benefit of a dry product is that it can be stored in ambient conditions
and solubilized for delivery, applied dry directly in a wound, mounted in a gel for sustained release,
embedded in materials, and even applied as a powder coating on a bulk material.
Growth factors are a part of the natural wound healing progression to cause cellular
migration, proliferation, and growth30, 33. Here it is seen that growth factors fall victim to proteases
secreted in a wound whether that be growth factors in a therapeutic or ones that are secreted as a
normal part of the wound healing cycle. This predicament has been displayed by other researchers
as well12, 18, 34. Therefore, any protein based therapeutic combination must protect itself, and
healthy tissues, through the addition of protease inhibitors to accompany growth factors. With this
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knowledge a thoughtful approach has been developed to yield this wound healing product that
spikes proliferation while interrupting tissue and protein degradation. Utilizing the engineered dual
protease inhibitor, PMPD2-L10Flag-APPIP, an all-encompassing protein cocktail harvested from
UM-MSCs, and an engineered tethering protein, all as a therapeutic protein-based combination is
valuable on both the level of therapeutic efficacy and economic practicality. Economically, protein
synthesis can be very expensive due to the sheer number of proteins that would need to be
synthesized and purified separately if a protein cocktail, like the um-MSC biproducts of
conditioning media, were to be made recombinantly. However, the utilization of stem cells to
condition media into a cocktail of growth factors and proteins is extremely cost effective and
utilizing it as a therapeutic is merely considered an allograft approach. Additionally, cloning and
recombinant technology utilized to create both PMPD2-L10Flag-APPIP and L10Flag-PlGF2 is a
cost-effective approach especially when working off of a elastin-like peptide backbone where
temperature alterations, pH changes, and centrifugation are the only driving forces to obtain a
purified product.
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Chapter 8: Key Developments
•

A multi-target protease inhibitor was constructed as a single protein molecule with the
ability to inhibit elastase and matrixmallproteinase-2, two proteases in elevated levels in
chronic wounds and delayed wounds.

•

The implementation of pI-Based Phase Separation during inverse transition cycling for the
successful and cost-effective purification of dual ELP-fusion proteins.

•

Protocols and processing procedures to harvest a potent growth factor cocktail that can be
mixed with ELP-fusion proteins and freeze-dried into a dry powder.

•

The combination of um-MSC conditioned media with the dual protease inhibitor, PMPD2L10Flag-APPIP, to yield a protein combination that is self-protecting from proteolytic
degradation in the wound site and protects healthy tissues that would otherwise be
unnecessarily degraded by high levels of protease.

•

The addition of a protein-based tethering system utilizing L10Flag-PlGF2 to further sustain
the presence and diffusional control of the dual inhibitor beyond the limitations of
aggregation caused by charge distribution and repulsive interactions between the bioactive
ends of the dual inhibitor.

•

The creation of a dry protein-based combination for the extension and ease of shelf life and
storage, versatility of application style, and application in harsh environments (i.e.
battlefields, underserved countries).
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A

Appendix A: Abbreviation Key
•

ELP: Elastin Like Peptide

•

ITC: Inverse Transition Cycling

•

pI: Isoelectric Point

•

HtHW: Hard-to-Heal Wound

•

MMP2: Matrix metalloproteinase-2

•

MSC-CM: Mesenchymal Stem Cell Conditioned Media

•

NE: Neutrophil Elastase

•

pI-BPS: Isoelectric Point-Based Phase Separation

•

Um-MSC: Umbilical Cord Derived Mesenchymal Stem Cells

80
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The permission below is for the use of material in Chapter 4 Sections 4.1-4.4, Section 2.2,
andSection6.1.
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